Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against the off-brand versions, citing safety concerns.
FDA receives reports almost daily from different food companies regarding potential allergens or foodborne illnesses.
The post Shooting the Messenger and Blaming the Victim appeared first on Reason.com. Just before 9 p.m. on Thursday, Dec. 19, ...
Following the recent approval of its Regadenoson generic drug by the United States Food and Drug Administration (FDA), Indies ...
The U.S. Food and Drug Administration (FDA) has announced a final rule updating the definition of the nutrient content claim “healthy.” To qualify ...
The US Food and Drug Administration wants to redefine the meaning of healthy food, issuing a new rule Thursday that changes ...
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...
Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug ...
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
AstraZeneca has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its ...
If your drug trials don't succeed, try again with another drug — and raise more money. That's $RAPT's plan as it targets food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback